Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24818614 | 0.96 | DPP4 (0.47) | L3MBTL1DPP4KMT2AMEN1TDP1 | |
| SCHEMBL10487028 | 0.86 | ATM (0.54) | L3MBTL1DPP4KMT2AMEN1TDP1 | |
| SCHEMBL2646670 | 0.83 | DPP4 (0.50) | L3MBTL1DPP4KMT2AMEN1TDP1 | |
| SCHEMBL13422266 | 0.83 | HTR1A (0.46) | L3MBTL1DPP4KMT2ATDP1ALDH1A1 | |
| SCHEMBL24322565 | 0.82 | HTT (0.56) | L3MBTL1ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3312154 | 0.82 | DPP4 (0.41) | L3MBTL1DPP4KMT2AMEN1TDP1 | |
| SCHEMBL18330367 | 0.80 | ALDH1A1 (0.56) | L3MBTL1DPP4KMT2AMEN1ALDH1A1 | |
| SCHEMBL20095024 | 0.79 | DPP4 (0.50) | L3MBTL1DPP4KMT2AMEN1TDP1 | |
| SCHEMBL8299375 | 0.79 | L3MBTL1 (0.49) | L3MBTL1DPP4KMT2ATDP1ATM | |
| SCHEMBL22349073 | 0.79 | L3MBTL1 (0.55) | L3MBTL1KMT2AMEN1TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | L3MBTL1 2569/4885DPP4 532/4885KMT2A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.